Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-279-9845
Debt
Debt-to-Equity Ratio0.81
Current Ratio4.51
Quick Ratio4.51
Price-To-Earnings
Trailing P/E Ratio-2.42
Forward P/E Ratio-3.84
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.14 per share
Price / Book5.49
Profitability
EPS (Most Recent Fiscal Year)($4.86)
Net Income$-42,440,000.00
Net MarginsN/A
Return on Equity-233.79%
Return on Assets-105.48%
Miscellaneous
Employees16
Outstanding Shares14,240,000
Market Cap$101.18 million
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its earnings results on Friday, August, 10th. The biotechnology company reported ($0.82) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.82). View Eiger Biopharmaceuticals' Earnings History.
When is Eiger Biopharmaceuticals' next earnings date?
What price target have analysts set for EIGR?
7 brokers have issued 12-month target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $24.00 to $53.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $33.2857 in the next twelve months. This suggests a possible upside of 183.3% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.
What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Scholar Rock (SRRK), PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG), Neon Therapeutics (NTGN), Adverum Biotechnologies (ADVM), Surface Oncology (SURF), ADMA Biologics (ADMA), Jounce Therapeutics (JNCE), Nantkwest (NK), MeiraGTx (MGTX), Allena Pharmaceuticals (ALNA), Agenus (AGEN), Fennec Pharmaceuticals (FENC), Idera Pharmaceuticals (IDRA) and Krystal Biotech (KRYS).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 54)
- Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 55)
- Mr. James A. Welch, Chief Financial Officer (Age 60)
- Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 53)
- Mr. James P. Shaffer, Chief Bus. Officer (Age 51)
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
Media headlines about EIGR stock have been trending positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a media and rumor sentiment score of 0.41 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Eiger Biopharmaceuticals.
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (11.92%), Prosight Management LP (4.16%), GMT Capital Corp (2.69%), Renaissance Technologies LLC (2.18%), BlackRock Inc. (2.08%) and P.A.W. Capital Corp (0.85%). Company insiders that own Eiger Biopharmaceuticals stock include Jeffrey S Glenn and Joanne Quan. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which major investors are selling Eiger Biopharmaceuticals stock?
Which major investors are buying Eiger Biopharmaceuticals stock?
EIGR stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, GMT Capital Corp, BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Ardsley Advisory Partners and Algert Global LLC. View Insider Buying and Selling for Eiger Biopharmaceuticals.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $11.75.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $101.18 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 350 CAMBRIDGE AVE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-279-9845 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
